{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Vistagen Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"VTGN"},"Address":{"label":"Address","value":"343 ALLERTON AVENUE,SOUTH SAN FRANCISCO, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 577-3600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression."},"CompanyUrl":{"label":"Company Url","value":"https://www.vistagen.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ester Salm√°n","title":"Vice President-Clinical Research"},{"name":"Joshua S. Prince","title":"Chief Operating Officer"},{"name":"Shawn K. Singh","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}